GI Cancer
Advertisement
Dr. Cecchini explains how ctDNA was used in this study as well as which methods were used for analyzing ctDNA levels.
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
The AI model used predictors of recurrence and duration imatinib treatment to determine recurrence risk.
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
Researchers examined TAS102 with regorafenib to determine if the combination is active in CRC and other GI malignancies.
While immunotherapy paired with VEGF inhibitors are considered first-line options, they only provide modest efficacy.
Dr. Timothy Brown speaks about his career and his passion for gastrointestinal oncology research and patient care.
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma.
Median OS was 9.1 months for patients with CP-B7 and 4.7 months for those with CP-B8-C12.
Dr. Arun Nagarajan explains how disparities in testing can affect survival and treatment outcomes for patients with mCRC.
The risk of developing esophageal cancer is between 30 and 125 times higher in patients with Barrett's esophagus.
The study investigated the Single Tremelimumab Regular Interval Durvalumab regimen.
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
A higher density of CD8+ T cells was linked to a more favorable PFS, but only to a limited extent.
The timing of stoma closure does not appear to affect long-term bowel function and quality of life.
The potential uses of bexarotene, a retinoid, for patients with colon cancer have not been adequately explored.
iTNT regimens were found to improve CR rates in patients with pMMR/MSS LARC compared with historical benchmark data.
While GEP-NETs are often torpid, the incidence of patients with GEP-NETs has increased over the last few years.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.